Nuveen Asset Management, LLC Athira Pharma, Inc. Transaction History

Nuveen Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.26 - $4.22 $42,449 - $79,264	-18,783 Reduced 20.35%	73,506 $183,000
Q4 2022 Feb 14, 2023	SELL	$2.76 - $3.71 $59,353 - $79,783	-21,505 Reduced 18.9%	92,289 $780,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $7,585 - $10,252	2,589 Added 2.33%	113,794 $961,000
Q2 2022 Aug 15, 2022	SELL	$2.74 - $13.43 $11,444 - $56,097	-4,177 Reduced 3.62%	111,205 $940,000
Q1 2022 May 16, 2022	BUY	$8.96 - $13.51 $11,002 - $16,590	1,228 Added 1.08%	115,382 $1.23 Million
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $100,218 - $179,126	-10,929 Reduced 8.74%	114,154 $1.47 Million
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $100,174 - $121,413	10,948 Added 9.59%	125,083 $1.27 Million
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $677,232 - $1.38 Million	66,136 Added 137.79%	114,135 $1.17 Million
Q1 2021 May 17, 2021	BUY	$16.9 - $29.77 $182,148 - $320,861	10,778 Added 28.96%	47,999 $883,000
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $613,402 - $1.28 Million	37,221 New	37,221 $1.28 Million

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.